Thermo Fisher Scientific Elotuzumab Polyclonal Antibody

Applications

Tested Dilution

Publications

ELISA (ELISA)

1:1,000-1:30,000

-

Immunoelectrophoresis (IE)

Neat

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Goat / IgG

Class

Polyclonal

Type

Antibody

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 6.8 to 7.4

Contains

0.09% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

Target Information

Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148. 1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U. S. Food and pharmaceutical Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.